Connor, Clark & Lunn Investment Management (CC&L)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.5M | Buy |
42,465
+10,301
| +32% | +$7.01M | 0.05% | 310 |
|
|
2026
Q1 | $24.9M | Buy |
+32,164
| New | +$24.6M | 0.06% | 275 |
|
|
2025
Q2 | – | Sell |
-1,917
| Closed | -$1.22M | – | 1656 |
|
|
2025
Q1 | $1.22M | Buy |
1,917
+983
| +105% | +$676K | 0.01% | 886 |
|
|
2024
Q4 | $665K | Sell |
934
-19,577
| -95% | -$16.4M | ﹤0.01% | 1063 |
|
|
2024
Q3 | $21.6M | Buy |
20,511
+11,008
| +116% | +$12.3M | 0.1% | 159 |
|
|
2024
Q2 | $9.99M | Buy |
9,503
+7,502
| +375% | +$7.27M | 0.04% | 280 |
|
|
2024
Q1 | $1.93M | Sell |
2,001
-185
| -8% | -$176K | 0.01% | 683 |
|
|
2023
Q4 | $1.92M | Sell |
2,186
-480
| -18% | -$395K | 0.01% | 676 |
|
|
2023
Q3 | $2.19M | Sell |
2,666
-14,287
| -84% | -$11.2M | 0.01% | 594 |
|
|
2023
Q2 | $12.2M | Sell |
16,953
-12,834
| -43% | -$9.9M | 0.06% | 228 |
|
|
2023
Q1 | $24.5M | Buy |
29,787
+11,581
| +64% | +$8.73M | 0.13% | 131 |
|
|
2022
Q4 | $13.1M | Buy |
18,206
+13,972
| +330% | +$10.3M | 0.08% | 195 |
|
|
2022
Q3 | $2.92M | Buy |
4,234
+1,106
| +35% | +$696K | 0.02% | 422 |
|
|
2022
Q2 | $1.85M | Sell |
3,128
-5,204
| -62% | -$3.38M | 0.01% | 488 |
|
|
2022
Q1 | $5.82M | Sell |
8,332
-9,407
| -53% | -$5.95M | 0.03% | 303 |
|
|
2021
Q4 | $11.2M | Buy |
17,739
+5,879
| +50% | +$3.61M | 0.05% | 226 |
|
|
2021
Q3 | $7.18M | Sell |
11,860
-13,124
| -53% | -$8.15M | 0.04% | 289 |
|
|
2021
Q2 | $14M | Sell |
24,984
-1,006
| -4% | -$510K | 0.07% | 202 |
|
|
2021
Q1 | $12.3M | Buy |
25,990
+17,687
| +213% | +$8.61M | 0.07% | 199 |
|
|
2020
Q4 | $4.01M | Buy |
8,303
+1,145
| +16% | +$618K | 0.02% | 384 |
|
|
2020
Q3 | $4.01M | Buy |
7,158
+2,310
| +48% | +$1.4M | 0.03% | 349 |
|
|
2020
Q2 | $3.02M | Buy |
4,848
+918
| +23% | +$521K | 0.02% | 386 |
|
|
2020
Q1 | $1.92M | Sell |
3,930
-16,070
| -80% | -$6.63M | 0.02% | 424 |
|
|
2019
Q4 | $7.51M | Buy |
20,000
+14,675
| +276% | +$4.94M | 0.05% | 220 |
|
|
2019
Q3 | $1.48M | Sell |
5,325
-12,225
| -70% | -$3.62M | 0.01% | 476 |
|
|
2019
Q2 | $5.49M | Buy |
17,550
+13,150
| +299% | +$4.38M | 0.04% | 268 |
|
|
2019
Q1 | $1.81M | Buy |
4,400
+1,575
| +56% | +$649K | 0.01% | 427 |
|
|
2018
Q4 | $1.05M | Sell |
2,825
-1,625
| -37% | -$595K | 0.01% | 542 |
|
|
2018
Q3 | $1.8M | Buy |
4,450
+625
| +16% | +$238K | 0.01% | 458 |
|
|
2018
Q2 | $1.32M | Sell |
3,825
-400
| -9% | -$125K | 0.01% | 562 |
|
|
2018
Q1 | $1.46M | Sell |
4,225
-725
| -15% | -$252K | 0.01% | 435 |
|
|
2017
Q4 | $1.86M | Buy |
4,950
+25
| +0.5% | +$10.1K | 0.01% | 427 |
|
|
2017
Q3 | $2.2M | Buy |
4,925
+625
| +15% | +$297K | 0.01% | 403 |
|
|
2017
Q2 | $2.11M | Buy |
4,300
+900
| +26% | +$394K | 0.01% | 382 |
|
|
2017
Q1 | $1.32M | Sell |
3,400
-1,700
| -33% | -$630K | 0.01% | 455 |
|
|
2016
Q4 | $1.87M | Buy |
5,100
+2,100
| +70% | +$799K | 0.01% | 383 |
|
|
2016
Q3 | $1.21M | Sell |
3,000
-2,300
| -43% | -$923K | 0.01% | 445 |
|
|
2016
Q2 | $1.85M | Buy |
5,300
+300
| +6% | +$116K | 0.01% | 376 |
|
|
2016
Q1 | $1.8M | Sell |
5,000
-6,700
| -57% | -$2.76M | 0.01% | 351 |
|
|
2015
Q4 | $6.35M | Sell |
11,700
-8,175
| -41% | -$4.43M | 0.05% | 186 |
|
|
2015
Q3 | $9.24M | Buy |
+19,875
| New | +$10.7M | 0.08% | 131 |
|
|
2014
Q1 | – | Sell |
-10,743
| Closed | -$3.14M | – | 760 |
|
|
2013
Q4 | $3.14M | Buy |
10,743
+4,793
| +81% | +$1.38M | 0.02% | 206 |
|
|
2013
Q3 | $1.91M | Buy |
5,950
+4,750
| +396% | +$1.25M | 0.02% | 201 |
|
|
2013
Q2 | $285K | Buy |
+1,200
| New | +$279K | ﹤0.01% | 433 |
|
Other funds holding REGN
Connor, Clark & Lunn Investment Management (CC&L)'s REGN Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) increased its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, buying an estimated $7.01M and bringing the position to 42,465 shares worth $26.5M. The position accounts for 0.05% of the portfolio, ranked #310.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in REGN in Q2 2013 and has held it in 44 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 42,465 shares of Regeneron Pharmaceuticals worth $26.5M as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) bought 10,301 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.01M.
- Regeneron Pharmaceuticals made up 0.05% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #310 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.